Cardiovascular drugs and the risk of suicide: a nested case-control study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Udgivelsesdato: 2007-Jun
OriginalsprogEngelsk
TidsskriftEuropean Journal of Clinical Pharmacology
Vol/bind63
Udgave nummer6
Sider (fra-til)591-96
Antal sider6
ISSN0031-6970
DOI
StatusUdgivet - 1. jun. 2007

Fingeraftryk

Case-Control Studies
Odds Ratio
Confidence Intervals
Angiotensin Receptor Antagonists
Registries
Pharmaceutical Preparations
Depression
Lipids
Psychotropic Drugs
Proxy
Denmark
Prescriptions
Logistic Models

Citer dette

@article{bda08560db0711dc860c000ea68e967b,
title = "Cardiovascular drugs and the risk of suicide: a nested case-control study",
abstract = "OBJECTIVE: During the past 30 years, various cardiovascular drugs have been implicated as causes of depression or suicide. Although the evidence for causal relationships has generally been conflicting, both beta-blockers and angiotensin-converting-enzyme inhibitors (ACE-inhibitors) have been related to depression. Lipid-lowering therapies and calcium-channel blockers have also been linked to an increased risk of suicide. In this study, we investigated the possible association between the use of cardiovascular drugs and suicide using population-based register data. METHODS: We performed a nested case-control study in the county of Funen, Denmark, that consisted of 743 cases of completed suicide identified in a Death Registry for the period 1991-1998 and 14,860 age- and sex-matched controls. Information on previous drug use was retrieved from prescription data and the association between suicide and use of cardiovascular drugs was analysed by conditional logistic regression. Previous exposures to other drugs were used as proxies for potential confounding co-morbidities, including the use of psychotropic drugs to indicate psychiatric illness. RESULTS: The risk of suicide was not associated with current exposure to lipid-lowering drugs [odds ratio (OR): 1.21; 95{\%} confidence interval (95{\%} CI): 0.45-3.28), calcium-channel blockers (OR: 0.96; 95{\%} CI: 0.63-1.48), beta-blockers (OR: 0.76; 95{\%} CI: 0.47-1.25) or ACE-inhibitors (OR: 1.11; 95{\%} CI: 0.68-1.83). Suicide risk was associated with current angiotensin-receptor antagonist use (OR: 3.52; 95{\%} CI: 1.33-9.30) based on five of the cases exposed. CONCLUSION: With the exception of the imprecise risk associated with current use of angiotensin-receptor antagonists, the results from our study do not support the hypothesis that other cardiovascular drugs are associated with an increased the risk of suicide.",
keywords = "Adult, Calcium Channel Blockers, Cardiovascular Agents, Case-Control Studies, Denmark, Depression, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Risk Factors, Suicide",
author = "Torbj{\"o}rn Callr{\'e}us and {Agerskov Andersen}, Ulla and Jesper Hallas and Morten Andersen",
year = "2007",
month = "6",
day = "1",
doi = "10.1007/s00228-007-0293-5",
language = "English",
volume = "63",
pages = "591--96",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Heinemann",
number = "6",

}

Cardiovascular drugs and the risk of suicide: a nested case-control study. / Callréus, Torbjörn; Agerskov Andersen, Ulla; Hallas, Jesper; Andersen, Morten.

I: European Journal of Clinical Pharmacology, Bind 63, Nr. 6, 01.06.2007, s. 591-96.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Cardiovascular drugs and the risk of suicide: a nested case-control study

AU - Callréus, Torbjörn

AU - Agerskov Andersen, Ulla

AU - Hallas, Jesper

AU - Andersen, Morten

PY - 2007/6/1

Y1 - 2007/6/1

N2 - OBJECTIVE: During the past 30 years, various cardiovascular drugs have been implicated as causes of depression or suicide. Although the evidence for causal relationships has generally been conflicting, both beta-blockers and angiotensin-converting-enzyme inhibitors (ACE-inhibitors) have been related to depression. Lipid-lowering therapies and calcium-channel blockers have also been linked to an increased risk of suicide. In this study, we investigated the possible association between the use of cardiovascular drugs and suicide using population-based register data. METHODS: We performed a nested case-control study in the county of Funen, Denmark, that consisted of 743 cases of completed suicide identified in a Death Registry for the period 1991-1998 and 14,860 age- and sex-matched controls. Information on previous drug use was retrieved from prescription data and the association between suicide and use of cardiovascular drugs was analysed by conditional logistic regression. Previous exposures to other drugs were used as proxies for potential confounding co-morbidities, including the use of psychotropic drugs to indicate psychiatric illness. RESULTS: The risk of suicide was not associated with current exposure to lipid-lowering drugs [odds ratio (OR): 1.21; 95% confidence interval (95% CI): 0.45-3.28), calcium-channel blockers (OR: 0.96; 95% CI: 0.63-1.48), beta-blockers (OR: 0.76; 95% CI: 0.47-1.25) or ACE-inhibitors (OR: 1.11; 95% CI: 0.68-1.83). Suicide risk was associated with current angiotensin-receptor antagonist use (OR: 3.52; 95% CI: 1.33-9.30) based on five of the cases exposed. CONCLUSION: With the exception of the imprecise risk associated with current use of angiotensin-receptor antagonists, the results from our study do not support the hypothesis that other cardiovascular drugs are associated with an increased the risk of suicide.

AB - OBJECTIVE: During the past 30 years, various cardiovascular drugs have been implicated as causes of depression or suicide. Although the evidence for causal relationships has generally been conflicting, both beta-blockers and angiotensin-converting-enzyme inhibitors (ACE-inhibitors) have been related to depression. Lipid-lowering therapies and calcium-channel blockers have also been linked to an increased risk of suicide. In this study, we investigated the possible association between the use of cardiovascular drugs and suicide using population-based register data. METHODS: We performed a nested case-control study in the county of Funen, Denmark, that consisted of 743 cases of completed suicide identified in a Death Registry for the period 1991-1998 and 14,860 age- and sex-matched controls. Information on previous drug use was retrieved from prescription data and the association between suicide and use of cardiovascular drugs was analysed by conditional logistic regression. Previous exposures to other drugs were used as proxies for potential confounding co-morbidities, including the use of psychotropic drugs to indicate psychiatric illness. RESULTS: The risk of suicide was not associated with current exposure to lipid-lowering drugs [odds ratio (OR): 1.21; 95% confidence interval (95% CI): 0.45-3.28), calcium-channel blockers (OR: 0.96; 95% CI: 0.63-1.48), beta-blockers (OR: 0.76; 95% CI: 0.47-1.25) or ACE-inhibitors (OR: 1.11; 95% CI: 0.68-1.83). Suicide risk was associated with current angiotensin-receptor antagonist use (OR: 3.52; 95% CI: 1.33-9.30) based on five of the cases exposed. CONCLUSION: With the exception of the imprecise risk associated with current use of angiotensin-receptor antagonists, the results from our study do not support the hypothesis that other cardiovascular drugs are associated with an increased the risk of suicide.

KW - Adult

KW - Calcium Channel Blockers

KW - Cardiovascular Agents

KW - Case-Control Studies

KW - Denmark

KW - Depression

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors

KW - Risk Factors

KW - Suicide

U2 - 10.1007/s00228-007-0293-5

DO - 10.1007/s00228-007-0293-5

M3 - Journal article

C2 - 17468865

VL - 63

SP - 591

EP - 596

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 6

ER -